XBP vs NIVF

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 03, 2026

XBP

38.6
AI Score
VS
NIVF Wins

NIVF

50.4
AI Score

Investment Advisor Scores

XBP

39score
Recommendation
AVOID NEW MONEY

NIVF

50score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric XBP NIVF Winner
Forward P/E 0 0.0071 Tie
PEG Ratio 0 0 Tie
Revenue Growth 4.7% 11.9% NIVF
Earnings Growth 0.0% 0.0% Tie
Tradestie Score 38.6/100 50.4/100 NIVF
Profit Margin 134.9% 209.0% NIVF
Beta 1.00 1.00 Tie
AI Recommendation AVOID NEW MONEY HOLD NIVF

Relative Price Performance (Last 90 Days)

XBP 1M: +12.6% · 3M: +29.2% NIVF 1M: -89.3% · 3M: -91.3%

Current Technical Phase

XBP

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (8.0% over 20 days), RSI 53

RSI (14): 52.8 · Price: $3.17

NIVF

Markdown
Sell / avoid

Price below a falling SMA50 (slope -19.7%), weak momentum, RSI 31

RSI (14): 31.2 · Price: $0.13

Fundamentals Snapshot

Metric XBP NIVF
Market Cap — —
Forward P/E -2.1 0.0
Trailing P/E — 0.0
Revenue (TTM) — —
Revenue Growth 0.0% 0.1%
Gross Margin 0.2% 0.2%
Operating Margin 0.0% -3.5%
EPS -3.89 197.38
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, NIVF is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.